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Background: Genetic amplification of HER2 drives tumorigenesis and cancer progression in a subset of patients
with gastric cancer (GC), and treatment with trastuzumab, a humanized HER2-neutralizing antibody, improves the
overall survival rate of HER2-positive patients. However, a considerable portion of the patients does not respond to
trastuzumab and the molecular mechanisms underlying the intrinsic resistance to anti-HER2 therapy in GC is not
fully understood.
Methods: We performed whole-transcriptome sequencing on 21 HER2-positive tumor specimens from Chinese GC
patients. Whole genome sequencing was performed on the three samples with HER2 fusion to discover the DNA
integration structure. A multicolor FISH assay for HER2 split screening was conducted to confirm HER2 fusion and
IHC (HercepTest™) was used to detect the membranous expression of HER2. Fusion cDNA were transfected into
NIH/3T3 cells and generate stable cell line by lentivirus. The expression of exogenous HER2 fusion proteins and pHER2
were examined by western blot analysis. In vitro efficacy studies were also conducted by PD assay and softagar assay in cell
line expression wild type and fusion HER2. T-DM1 was used to assess its binding to NIH/3T3 cells ectopically expressing
wild-type and fusion HER2. Finally, the anti-tumor efficacy of trastuzumab was tested in NIH/3 T3 xenografts expressing the
HER2 fusion variants.
Results: We identified three new HER2 fusions with ZNF207, MDK, or NOS2 in 21 HER2-amplified GC samples
(14%; 3/21). Two of the fusions, ZNF207-HER2, and MDK-HER2, which are oncogenic, lead to aberrant activation
of HER2 kinase. Treatment with trastuzumab inhibited tumor growth significantly in xenografts expressing MDK-HER2
fusion. In contrast, trastuzumab had no effect on the growth of xenografts expressing ZNF207-HER2 fusion, due to its
inability to bind to trastuzumab.
Conclusions: Our results provide the molecular basis of a novel resistance mechanism to trastuzumab-based anti-HER2
therapy, supporting additional molecule stratification within HER2-positive GC patients for more effective therapy options.
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Gastric cancer (GC), as the second leading cause of can-
cer deaths worldwide, accounted for 989,600 new cases
and 738,000 deaths globally in 2011 [1]; more than 50%
of GC cases occur in Eastern Asia [2]. The conventional
treatments for GC include surgery, radiotherapy and* Correspondence: qsji18@yahoo.com
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unless otherwise stated.chemotherapy [3], which have limited efficacy because
most GC patients are in the advanced stages when diag-
nosed; the five-year survival rate for patients with stage
III/IV GC is around 10% [4]. Trastuzumab, a neutralization
antibody of HER2, was recently approved for the treatment
of a subset of advanced GC patients whose tumors are
clinically defined as HER2-positive.
HER2 gene amplification was initially discovered as an
oncogene in breast cancer (BC), which led to the develop-
ment of HER2-targeted therapeutics for treating HER2-
positive BC [5]. These drugs include trastuzumab; lapatinib,
a small-molecular inhibitor of HER2 kinase; pertuzumab,
an antibody-blocking heterodimerization of HER2 withis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Yu et al. Journal of Translational Medicine  (2015) 13:116 Page 2 of 13HER3; and trastuzumab emtansine (T-DM1), which is tras-
tuzumab conjugated with the antimitotic agent emtansine
(DM1). The clinical application of these targeted agents
dramatically changed the landscape of BC therapy and ex-
emplified a new era of personalized medicine associated
with companion molecular diagnosis for patient selection
[6-8]. In addition to BC, HER2 amplification and overex-
pression was also found in about 20% of GC patients [9].
The anti-tumor activity of trastuzumab as a single agent or
in combination with cytotoxic agents has been demon-
strated in several HER2-positive human GC cell lines
in vitro and in GC xenografts in vivo [10-12]. The preclin-
ical efficacy translated into positive clinical trials in which a
survival improvement was achieved in HER2-positive meta-
static GC patients treated with trastuzumab plus cytotoxic
agents [9,13]. These results led to the approval of trastuzu-
mab as the first molecular targeted therapy for treating GC.
Despite the clinical benefits of trastuzumab in the treat-
ment of patients with HER2-positive GC or BC [13,14],
approximately 30-40% of HER2-positive tumors are in-
sensitive to the treatment. Significant efforts to under-
stand the resistance to anti-HER2 therapy in BC cases
have recently been made, resulting in a diverse array of re-
sistance mechanisms and clinical strategies to overcome
the resistance [15]. However, there is little understanding
of the resistance mechanism to anti-HER2 therapy in GC.
Therefore, we used a next-generation sequencing (NGS)
approach to elucidate molecular insights in HER2-positive
GC. In this study, for the first time, we report three HER2
gene fusions in HER2-positive GC in Chinese patients,
and we characterize their oncogenic properties and sensi-
tivity to anti-HER2 agents.
Methods
Human primary tumor samples
Specimens were collected during surgery from Chinese
GC patients with postoperative pathological confirm-
ation. The study was carried out at Peking University
Cancer Hospital and Institute, and Shanghai Renji Hospital
(2007 ~ 2010). Written informed consent was provided by
each patient, and the study was approved by the ethics
committees of the hospitals.
RNA-seq for transcriptome analysis
Total RNA was extracted using TRIzol (Life Technologies).
All RNA samples showed RNA integrity numbers >7
(Agilent 2100 bioanalyzer).
Total RNA quality and concentration was measured
using an RNA Pico chip on a Bioanalyzer 2100 (Agilent).
Normalized starting quantities of total RNA were used
to prepare Illumina sequencing libraries with a TruSeq™
RNA sample preparation kit (Illumina). The library prepar-
ation was performed according to the manufacturer’s in-
structions. The cDNA libraries were placed on an Illuminac-Bot for paired-end (PE) cluster generation, according to
the protocol outlined in the Illumina HiSeq Analysis User
Guide. The template cDNA libraries (1.5 μg) were hybrid-
ized to a flow cell, amplified, linearized, and denatured to
create a flow cell with ssDNA ready for sequencing. Each
flow cell was sequenced on an Illumina HiSeq2000 sequen-
cing system. After a 100-cycle PE sequencing run, the
bases and quality values were generated for each read with
the current Illumina pipeline.
Detection of fusion transcripts
We sequenced each tumor sample up to an average of
about 150× coverage. Fusion transcripts were detected
using FusionMap software [16]. Fusions supported by at
least three reads were selected as candidates and sub-
jected to RT-PCR and Sanger sequencing confirmation.
Quantification of mRNA expression level
Human gene expression quantification was measured
according to sequenced fragments (reads) per kilobase of





N: number of reads mapped in gene
L: gene length (bp) (intron excluded)
R: number of raw reads
RT-PCR and Sanger sequencing
First strand cDNA synthesis was performed with 0.5 μg total
RNA using a High Capacity cDNA Reverse Transcription kit
(Life Technologies) according to the manufacturer’s instruc-
tions. PCR was performed in a 25-μL reaction mix contain-
ing 1× AmpliTaq Gold® 360 Master Mix (Life Technologies),
200 μM of each primer, and 2 μL of cDNA. The PCR cycling
conditions were: 10-min incubation at 95°C, followed by
40 cycles of 94°C for 30 s, 60°C for 30 s, 72°C for 60 s, and a
final incubation at 72°C for 10 min. The resulting PCR prod-
ucts were digested with ExoSAP-IT reagent (Affymetrix,
Cleveland, OH) and then sequenced in forward and reverse
directions with a BigDye Terminator Kit (Life Technologies)
and an ABI 3730XL DNA analyzer (Life Technologies), fol-
lowing the manufacturer’s instructions. The sequencing data
were analyzed for mutations after assembly and quality call-
ing with SeqScape sequence analysis software (version 2.5;
Life Technologies). The RT-PCR primers used for fusion




Reverse: 5'-AGACCATAGCACACT CGGGCACA-3'; 3)
NOS2/HER2, Forward: 5’-CAAGCCCCACAGTGAAGAA
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Whole genome sequencing
DNA was extracted from the frozen tissues using a Pure-
gene DNA extraction kit (Qiagen) and quantified using a
PicoGreen fluorescence assay (Qubit; Invitrogen). To con-
duct whole genome sequencing, 2 μg of DNA were required
for each sample. After electrophoresis, DNA fragments of
the desired length were gel purified. Adapter ligation and
DNA cluster preparation were performed and subjected to
Illumina Hiseq2000 sequencing. Two paired-end libraries
with an insert size of 500 bp were prepared for all samples,
after which four lanes from each library were subjected to
whole genome sequencing. Raw image files were processed
by Illumina Pipeline for base calling with default parameters,
and the sequences of each individual were generated as
90-bp paired-end reads. Raw sequence data was mapped
to the reference human genome (hg19) using Bowtie 2.
The total mapping rate was >90%, and the average cover-
age was about 30×. Unmapped reads were then used to
conduct genomic fusion detection with FusionMap [16].
Analysis of HER2, BRAF, KRAS, or PI3K mutations
HER2, BRAF, KRAS, and PIK3CA gene mutations from
the RNAseq data were analyzed using ArrayStudio soft-
ware (http://www.omicsoft.com/array-studio.php). Allele
frequencies below 10% were removed in case of potential
false positive. The mutation status was further confirmed
by the whole genome sequencing data.
Immunohistochemistry (IHC)
The primary antibodies used to detect the cytoplasmic
domain of HER2 were purchased from Merck and
Abcam, and the antibody used to detect the external
domain of HER2 was purchased from Abnova. All of
the collected tissues were fixed in FFPE blocks. Xenograft
and cell-block sections were cut at 3 μm and human
sections were cut at 4 μm for the HER2 IHC study.
Paraffin sections were dewaxed and rehydrated in a
Leica XL autostainer. Following antigen retrieval, the sec-
tions were incubated with 10 min of endogenous peroxid-
ase block (DAKO), 60 min of primary antibodies, 30 min
of EnVision System-HRP labeled polymer anti-mouse
(DAKO), and 10 min of diaminobenzidine substrate
(DAKO K3468), in that order. Finally, the sections
were counter-stained, dehydrated, cleared, and mounted
with coverslips in a Leica XL autostainer workstation. A
HercepTest™ (DAKO) was used to detect the membran-
ous expression of HER2, following standard procedures.
Each slide was evaluated and scored on a 0–3 scale,
following uniform guidelines developed for GC HER2
scoring from ToGA trials [13].Fluorescent in situ hybridization (FISH)
A multicolor FISH assay for HER2 split screening was
conducted via a dual-probe FISH break-apart test. The
N-terminal and C-terminal probes for HER2 were gener-
ated internally by directly labeling BAC (N-terminal: RP11-
98 J2; C-terminal: RP11-1044P23) DNA respectively with
Green-dUTP (ENZO, Cat # 02 N32-050) and Red-dUTP
(ENZO, Cat #02 N34-050). A CEP17 spectrum aqua probe
(Vysis, Cat #32-131017) for the centromeric region of
chromosome 17 was used as an internal control of the
HER2 break-apart probes. Multicolor FISH was also used
to confirm HER2 gene fusion with certain partner genes.
The ZNF207 and NOS2 FISH probes were generated in-
ternally by directly labeling BAC (ZNF207: RP11-55 J8;
NOS2: RP11-696H14) DNA with gold 525-dUTP (ENZO,
Cat #ENZ42843). The FISH assays were performed as pre-
vious reported [17]. Briefly, the assay was run on 4-μm
dewaxed and dehydrated FFPE TMAs. A SPoT-Light tissue
pretreatment Kit (Invitrogen, Cat #00-8401) was used for
the pretreatment (boiled in reagent 1 for ~18 minutes,
then coated with reagent 2 for ~14 minutes, minor time
adjustments were made for individual samples). The sec-
tions and probes were co-denaturated at 79°C for 6 minutes
and then hybridized at 37°C for 48 hours. After a quick
post wash off process (0.3% NP40/2xSSC at 75.5°C for
2 minutes, twice in 2 × SSC at room temperature for
2 minutes), the sections were mounted with 0.3 μg/ml
DAPI (Vector, Cat #H-1200) and stored at 4°C, avoid-
ing light for at least 30 minutes prior to observation.
The FISH signals were observed using a fluorescence
microscope equipped with the appropriate filters, allowing
visualization of the intense red/green/gold signals of the tar-
get genes, the intense aqua centromere signals, and the blue
counterstained nuclei. A minimum 100 nuclei were scored
for each sample. Only nuclei with a minimum of two green
and two red signals were scored. In the break-apart assay,
fused N-terminal (green) and C-terminal (red) signals rep-
resent a normal HER2 gene. HER2 amplification status was
defined as a ratio of fused HER2 signals to CEP17 (aqua) ≥2.
The following situations indicated the presence of
HER2-involved fusion: 1) broken apart: more than
one set of broken-apart N-terminal and C-terminal
signals in ≥10% tumor cells; 2) N-terminal deletion:
more C-terminal signals in addition to fused and/or
broken-apart signals in ≥30% tumor cells. Then, a
multicolor FISH assay was performed on HER2 broken
apart or N-terminal-deleted positive cases. The HER2
fusion was confirmed when HER2 C-terminal red signals
co-localized with a certain partner gene’s gold signals.
Vector construction, cell culture, transduction, and
transformation studies
ZNF207-HER2 and MDK-HER2 fusion cDNA were syn-
thesized (Additional file 1: Files S1 and S2) at Generay
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PLVX lentiviral vector (Sunbio, China). The integrity of
the inserted cDNA was verified by Sanger sequencing of
the constructs. Lentiviruses expressing ZNF207-HER2
and MDK-HER2 fusions were produced according to the
manufacturer’s instructions. NIH/3 T3 fibroblast cells
were infected with lentiviruses expressing empty vec-
tor, and ZNF207-HER2 and MDK-HER2 fusions were
treated with puromycin (2 μg/ml) for two weeks. NIH/3 T3-
resistant cells were seeded on 96-well plates (2000 cells/well)
in 0.33% agar in complete medium. The expression of ex-
ogenous HER2, ZNF207-HER2, and MDK-HER2 proteins
and phosphorylation of HER2 were examined by immune
blot analysis. The overnight cell cultures in liquid or
soft agar medium were treated with lapatinib, T-DM1
(synthesized at ChemPartner, Shanghai, China) for 3
and 14 days, respectively. The cell growth rate was
measured by MTS assay according to the manufac-
turer’s instructions (Promega).Immunoblot analysis
Total cellular extracts from the cell lines were prepared in
an SDS lysis buffer supplemented with protease inhibitors
and phosphatase inhibitors (Sigma). Protein samples were
fractionated by SDS-PAGE and blotted onto polyvinyli-
dene difluoride membranes (Millipore). After incubation
with the indicated antibodies at 4°C overnight, the blots
were detected with the relevant horseradish peroxidase-
conjugated anti-mouse or anti-rabbit IgG antibody and
enhanced chemilluminescence (GE Healthcare). The anti-
body information used in the Western blot assays are
included were as follows: pHER2 (Y1221/1222) (CST,
Cat #2243, diluted 1:1000); HER2 (CST, Cat #2165, diluted
1:1000); pErk1/2 (T202/Y204) (CST, Cat #4376, diluted
1:1000); Erk1/2 (CST, Cat #9102, diluted 1:1000); pAKT
(Ser473) (CST, Cat# 9271, diluted 1:1000); and AKT (CST,
Cat #9272, diluted 1:1000).Trastuzumab emtansine (T-DM1) receptor binding assay
Approximately 5 × 105 NIH/3T3 cells expressing vector
control, wild-type HER2, ZNF207-HER2, or MDK-HER2
were collected using enzyme-free cell dissociation buf-
fer (Invitrogen). After blocking with 10% donkey serum
for 30 minutes at 4°C, the cells were incubated with
10 μg/mL T-DM1 (ChemPartner) at 4°C for one hour.
The cells were rinsed three times with wash buffer
(0.5% BSA in PBS) and further incubated with 10 ug/mL
Alex488 labeled donkey anti-human IgG (Jackson immun-
ology) at 4°C for one hour. After rinsing five times with
wash buffer, the mean intensity of the fluorescence was
detected by FACSCanto (BD). The receptor binding
was qualitatively evaluated by the peak shift in the
histogram.In vivo efficacy study in xenograft models
6- to 8-week-old female nude (nu/nu) mice (Vital River,
Beijing, China) were used for in vivo efficacy studies. All
experiments using immunodeficient mice were carried
out in accordance with the guidelines approved by the
Institutional Animal Care and Use Committees. NIH/3 T3
cells expressing ZNF207-HER2, MDK-HER2, or a control
vector were inoculated subcutaneously into female
nude mice. Tumor-bearing mice with tumors ranging
100–200 mm3 in size were selected randomly and
placed in groups according to their tumor volume and
body weight (eight animals per group) for treatment.
Trastuzumab (15 mg/kg) was administrated by intra-
venous injection twice a week. The xenograft tumors
were measured in two perpendicular diameters with a
caliper, and tumor volumes (TV) were calculated using
the formula TV = (length × width2)/2. Percentage of tumor
growth inhibition (%TGI) was calculated using the
formula [1-(change of tumor volume in treatment
group/change of tumor volume in control group)] × 100,
and was used to evaluate anti-tumor efficacy. Student’s t tests
were used to compare the TGI of the treatment group with
that of the control group. Statistical tests were two sided,
with P < 0.05 considered significant.
Results
Novel HER2 fusion genes identified in HER2-positive
gastric cancer
To uncover the genetic aberrations that might confer re-
sistance to trastuzumab treatment in GC, we performed
whole-transcriptome sequencing (RNAseq) on 21 HER2-
positive tumor specimens from Chinese GC patients
whose tumors were surgically removed and who were
treatment naïve, using the HiSeq2000 system (Illumina).
A number of candidate fusion transcripts were identi-
fied with more than three chimerical reads, which were
subsequently followed by RT-PCR/Sanger sequencing
confirmation. This led to the identification of three HER2
(chr17q12) in-frame fusion transcripts with 5’ partners
of ZNF207 (chr17q11.2), MDK (chr11p11.2), or NOS2
(chr17q11.2) in three HER2-positive GC samples of GC196,
431-9540474 T, and GC334, respectively (Figure 1A, B
and Table 1).
To understand the genomic alterations of these fusion
transcripts, tumor DNA samples from the three corre-
sponding GC patients were analyzed by whole genome
sequencing. Consistent with the data from the RNAseq
analysis, three HER2 fusion genes—ZNF207 (exon 1–2)/
HER2 (exon 18–30), MDK (exon 1–4)/HER2 (exon 11–
30), and NOS2 (exon 1–2)/HER2 (exon 2–30)—were fur-
ther confirmed in these tumor DNA samples (Figure 2).
These results demonstrate the existence of three novel
HER2 gene fusions in this cohort of HER2-positiv GC
patients.
Figure 1 Identification of HER2 fusions in gastric cancer. A. Schematic illustration of the wild-type HER2 protein and the three fusions identified
in this study. The breakpoints for each fusion are indicated by arrows. B. Sanger sequencing of the fusion junctions.
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In the GC196 sample, over 100 reads were detected for
ZNF207 genomic sequences only composing the 5’ partner
and HER2 sequences only composing the 3’ partner of the
ZNF207-HER2 fusion; low reads (~20) were captured for
the genomic sequences outside the fusion gene. In the
GC334 specimen, in addition to the high reads (>1800) of
the fusion partners of NOS2-HER2 fusion that were de-
tected, an average of 500 reads was also captured for the
entire genomic sequence of wild-type HER2 gene.
Next, we assessed the relative mRNA expression levels
of the three amplified fusion genes. Consistent with the
whole genome sequencing data, high levels of mRNA
expression of the three fusion variants were obtained in
the three HER2-fusion-positive tumor specimens (GC196
FPKM 346, 431-9540474 T FPKM 1359, and GC334 FPKMTable 1 A summary of patients with gastric cancer harboring
Samples Country Sex Age
GC196 China M 76
431-9540474 T China M 63
GC334 China F 62
*The amplification of MDK-HER2 was determined by aCGH, whereas the other two H2805). In the tumor harboring ZNF207-HER2, the increased
expression of HER2 mRNA was observed only after the fu-
sion site, whereas the increased expression of ZNF207
mRNA was detected only before the fusion site, further
confirming that the amplification of the ZNF207-HER2 fu-
sion was a homogeneous event in the sample (Figure 3A).
In contrast, in the tumor harboring MDK-HER2, overex-
pressed transcripts were detected for MDK-HER2 fusion,
wild-type HER2, and wild-type MDK, consistent with the
heterogeneity populations of amplified wild-type HER2 with
MDK-HER2 (Figure 3B). A similar observation was made in
the GC334 sample, in which overexpression of both NOS2-
HER2 and wild-type HER2 were detected (Figure 3C).
Given that the tumor samples harboring the three fusions
were all HER2-positive, we first developed a multicolor
fluorescence in situ hybridization (FISH) assay to assess
the genetic amplification status of the ZNF207-HER2HER2 fusions




ER2 fusion amplifications were defined by FISH and IHC assays.
Figure 2 Schematic of genomic fusion structure of the HER2 fusion. A. Genomic fusion structure for sample GC196 harboring ZNF207-HER2
fusion B. Genomic fusion structure for sample 431-9540474 T harboring MDK-HER2 fusion C. Genomic fusion structure for sample GC334 harboring
NOS2-HER2 fusion. The genomic structure was discovered by whole genome sequencing.
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their relationship to the wild-type HER2 gene in the
GC196 and GC334 samples, respectively. Based on
hematoxylin and eosin staining, both primary tumors
with the two HER2 fusions were defined as adenocar-
cinoma by pathologists (Figure 4A). The multicolor
FISH assay detected the N-terminal and C-terminal of
the HER2 gene, along with the ZNF207 or NOS2 gene.
As shown in Figure 4B, the ZNF207-HER2 fusion gene was
amplified homogeneously without wild-type HER2 amplifi-
cation in the GC196 sample. However, co-amplification of
both NOS2-HER2 and wild-type HER2 were observed in
the GC334 specimen, but in separate tumor cell popula-
tions (Figure 4C). The co-localization of 5’ partners and
the C-terminus of HER2 gene by the FISH analysis not
only further confirmed the genomic fusions of the involved
genes, but also indicated the intratumoral heterogeneity
within the HER2-amplified tumor. For the MDK-HER2 fu-
sion, although a formalin-fixed and paraffin-embedded
(FFPE) sample of 431-9540474 T was unavailable for the
multicolor FISH analysis, the whole genome sequencing
data suggested a mixture of tumor cell populationsharboring gene amplifications of wild-type HER2, MDK-
HER2, and wild-type MDK (Figure 3).
Lastly, we performed immunohistochemistry (IHC)
with a HercepTest™ in FFPE samples of GC196 and
GC334. Strong staining (IHC 3+) was detected in both
samples (Figure 4D), indicating an overexpression of the
HER2 proteins. A summary of the HER2 fusion status
was shown in Table 2.
Together, these data demonstrate the gene amplifica-
tion of the HER2 fusions, which correlated with dis-
regulation of both mRNA and protein expressions of
the fusion variants. In addition, the HercepTest™ did
not distinguish the fusion proteins from the wild-type
HER2.
Oncogenic driver activity of the HER2 fusions
A number of genetic aberrations with oncogenic properties
have been reported recently in GC cases [8]. Thus, we
aimed to determine whether the HER2 fusions overlapped
with the known oncogenic alterations. RNAseq and WGS
data showed that the three HER2-fusion-positive GC pa-
tients were negative for HER3, BRAF, KRAS, PI3KCA, and
Figure 3 Illustration of DNA coverage and mRNA expression levels of HER2 and fusion partners. A. DNA coverage and mRNA expression levels of
HER2 and ZNF207 in sample GC196. B. DNA coverage and mRNA expression levels of HER2 and MDK in sample 431-9540474 T C. DNA coverage
and mRNA expression levels of HER2 region (including HER2 and nearby gene STARD3, TCAP, PNMT, PGAP3 and MIEN1) and fusion partner NOS2 in
sample GC334. The DNA integration sites were marked in green arrows and the RNA fusion junction sites were marked in cyan arrows. Exon
coverage was shown in red and intron coverage was shown in blue. The coverage range for each gene was given in the right side of the figure.
Average coverage for WGS is 30X and average coverage for RNASeq is 150X.
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and cMET (data no shown), which are common gen-
etic alterations identified in GC [18]. The mutually ex-
clusive nature of HER2 fusions from these known
oncogenic alterations suggests that the HER2 fusions
are oncogenic drivers. In addition, sequence analysis
revealed that proteins encoded by ZNF207-HER2 and
MDK-HER2 fusion variants contained a partial extra-
cellular domain, a transmembrane domain, and a full
kinase domain of HER2 (Additional file 1: Files S1 and S2),
whilst the predicated fusion protein of NOS2-HER2 would
be a full-length HER2 protein as result of a stop codon that
is introduced prior to the HER2 start codon (Additional file
1: File S3). Based on the sequence predication that NOS2-
HER2 fusion encodes a full-length HER2 without NOS2,
our efforts on function characterization of these HER2
fusion proteins were then focused on ZNF207-HER2
and MDK-HER2 fusions.Given the presence of the HER2 dimerization domain
[19,20], ZNF207-HER2 and MDK-HER2 fusion variants are
likely to form homodimers in a manner similar to that of
amplified wild-type HER2. Consistently, when MDK-HER2
and ZNF207-HER2 variants were ectopically expressed in
NIH/3 T3 cells, the autophosphorylation sites Tyr1221/
1222 at the C-terminus of HER2 involved in the activation
of HER2 signaling were phosphorylated in a similar manner
as wild-type HER2 [21] (Figure 5A). This result indicates
an aberrant activation of HER2 kinase by the fusions with
MDK or ZNF207. Downstream-signaling AKT was also
phosphorylated by the fusion variants (Figure 5A).
Phospho-HER2Y1221/1222 and phospho-AKTS473 were
suppressed by Lapatinib (Figure 5A), thus predicting the
sensitivity of GC harboring the HER2 fusions to the HER2
kinase inhibitor, such as Lapatinib.
In addition to the induction of phosphorylation of
Tyr1221/1222, the exogenous expression of ZNF207-HER2
Figure 4 Amplification and over-expression of HER2 fusions in gastric tumors. A. Histological characterization of human gastric carcinomas.
Representative images from H&E staining of GC196 and GC334 primary tumors. B. ZNF207-HER2 gene fusion in primary tumor GC196. Representative
images of break-apart FISH on GC196 shows normal copy of HER2 N-terminal (green signals), coexistence of amplified HER2 C-terminal (red signals) and
amplified ZNF207 (gold signals). Red and green signals represent C-terminal (HER2-C-SR) and N-terminal (HER2-N-SG) of HER2 gene, respectively;
gold signals represent whole length of ZNF207 gene (ZNF207-WL-SGo); aqua signal represent CEP17 as internal control. Cell nuclei were
counterstained with DAPI. C. NOS2-HER2 gene fusion in tumor GC334 primary tumor. Representative images of break-apart FISH on GC334
show NOS2-HER2 fusion with heterogeneity. The upper lane showed tumor cells with both HER2 N-terminal (green signals) and C-terminal (red signals)
amplified and normal copy number of NOS2 (gold signals). The lower lane showed tumor cells with normal copy of HER2 N-terminal (green signals),
coexistence of amplified HER2 C-terminal (red signals) and amplified NOS2 (gold signals). Red and green signals represent C-terminal and N-terminal of
HER2 gene; gold signals represent NOS2 gene; aqua signal represent CEP17 as internal control. Cell nuclei were counterstained with DAPI. D. IHC analysis
of HER2. Representative images showed HER-2 IHC strong membrane staining (+++) on GC196 and GC334 primary tumors.
Table 2 A summary of the HER2 fusion status
Sample ID Fusion Type(RNA) DNA structure 5' fusion partner status HER2 status





Gene copy N Ter AMP Gene Copy C Ter AMP
Protein level - Protein level IHC 3+
431-9540474 T MDK_exon4 -/HER2_exon11 MDK_intron4/HER2_intron10 MDK mRNA expression High mRNA
Expression
High
Gene copy tAMP Gene Copy tAMP
Protein level - Protein level -





Gene copy N Ter AMP Gene Copy tAMP
Protein level - Protein level IHC 3+
N Ter AMP: N terminal amplification.
C Ter AMP: C terminal amplification.
tAMP: total amplification.
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Figure 5 Transformation of NIH/3T3 cells by ZNF207-HER2 and MDK-HER2 fusions. A. Modulation of HER2 signaling in NIH/3 T3 cells
expressing HER2 fusions. Cell lysates collected from cells stably expressing HER2 and HER2 fusions were subjected to western blotting analysis
with antibodies against phospho and total HER2, Akt and Erk. B. Exogenous expression of ZNF207-HER2 and MDK-HER2 led to transformational
morphological changes. Cells were photographed under a phase-contrast light microscope (×150) under identical conditions. C. Anchorage-independent
growth of NIH/3 T3 cells expressing HER2 fusions. Cells were seeded in soft agar culture in 96-well plates for 14 days and colony formation
was photographed under a phase-contrast light microscope (×150). The results are representative from three independent experiments.
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transformational morphology (Figure 5B); anchorage-
independent growth of the cells in vitro, which was
comparable to the oncogenic phenotypes caused by
mutant KRAS (V12D) (Figure 5C). Together, these results
demonstrate the oncogenic properties of the ZNF207-
HER2 and MDK-HER2 fusions in GC.
Different binding and responsiveness of the HER2 fusions
to T-DM1 and trastuzumab
To determine whether the 5’ partners fused to a trun-
cated HER2 extracellular domain affects their binding
ability to trastuzumab in the two HER2 fusion variants,
we used T-DM1 to assess its binding to NIH/3 T3 cells
ectopically expressing wild-type HER2, MDK-HER2, or
ZNF207-HER2. Our results clearly showed that under
those conditions, the ZNF207-HER2 fusion lost itsability to bind to T-DM1, while MDK-HER2 bound to
T-DM1 in a manner similar to that of wild-type HER2
(Figure 6A). Because the receptor binding assay was
performed using the engineered cells, it might be argued
that the impaired binding of ZNF207-HER2 could be due
to improper cellular localization of the fusion protein. To
address this issue, cellular localization of ectopically
expressed MDK-HER2 or ZNF207-HER2 in the NIH/3 T3
cells was assessed by HercepTest™. As shown in Figure 6B,
strong membrane staining (IHC 3+) was observed in the
NIH/3 T3 cells expressing MDK-HER2 or ZNF207-HER2,
similar to the results observed in the original primary
tumor samples (Figure 4D), thus further supporting the in-
ability of ZNF207-HER2 to bind to T-DM1.
The different binding capabilities of the HER2 fusions
to T-DM1 predict different responsiveness of GC cells
with the HER2 fusions to trastuzumab-based anti-HER2
Figure 6 Binding of the HER2 fusions with T-DM1. A. Cells were incubated with T-DM1 at 4°C for 1 hr and the bound T-DM1 was measured
by FACS with an Alex488 labeled secondary antibody. The results are representative from three independent experiments. B. IHC analysis of HER2
with HercepTest™).
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of cells expressing wild-type HER2 or MDK-HER2 fu-
sion, but this inhibitory effect was significantly im-
paired in the cells expressing the ZNF207-HER2 fusion
(Figure 7A), indicating an intrinsic resistance mechanismFigure 7 Response of NIH/3T3 cells expressing HER2 fusions to T-DM1
fusions to T-DM1. Cells were treated with T-DM1 at indicated concentration
error bars represent SD. B-C. Anti-tumor efficacy of trastuzumab in xenogra
xenografts stably expressing the MDK-HER2 (B) or ZNF207-HER2 fusion va
the tumor size was measured with a caliper. The error bars represent SE
the treatment group with that in the control group *: P < 0.05.to trastuzumab-based therapy. The resistance of ZNF207-
HER2 to T-DM1 was further confirmed in in vivo efficacy
study. We tested the anti-tumor efficacy of trastuzumab in
NIH/3 T3 xenografts expressing the ZNF207-HER2 or
MDK-HER2 fusion variant. As expected, the trastuzumaband trastuzumab. A. Response of NIH/3 T3 cells expressing HER2
s for 72 hrs and cell proliferation was measured by MTS assay. The
ft models expressing the HER2 fusions. Nude mice bearing NIH/3 T3
riant (C), were treated with trastuzumab at 15 mg/kg biweekly and
M and students’ T-tests were used to compare the growth rate in
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in the xenografts expressing the MDK-HER2 fusion
(TGI = 67%) (Figures 7B), but it showed no efficacy in
the xenografts expressing the ZNF207-HER2 fusion
(TGI = 2%) (Figures 7C), thus supporting the resistant
mechanism to trastuzumab in GC.
In summary, our results clearly demonstrate that the
ZNF-207-HER2 fusion does not respond to trastuzumab,
due to the loss of its binding ability.
Discussion
Several studies have recently used NGS to understand
the molecular basis of GC, and a number of previously
unknown genetic alterations have been reported [22], in-
cluding genetic fusions of HER2 in human GC cell lines.
For example, two HER2 fusions were identified at the
same time in human GC cell line MKN7 (HER2 posi-
tive): a fusion between CDK12 exon 12 and HER2 intron
4, and a second fusion between NEUROD2 exon 1 and
HER2 exon 8 [22]. However, there was no direct evidence
in that report that demonstrated the oncogenic driver of
these HER2 fusions. In the current study, we performed a
whole-transcriptome sequencing of 21 HER2-positive GC
tumor samples taken from Chinese patients, and discov-
ered three HER2 fusion transcripts due to HER2 gene fu-
sions. Two of them, ZNF207-HER2 and MDK-HER2 were
truncated in the N-terminal extracellular domains, but they
remained intact in the kinase and transmembrane domains
of HER2. The amplification and overexpression of the
three HER2 gene fusions were detected in the primary GC
samples by multicolor FISH and RNAseq or IHC-based
HercepTest™ analysis. The ectopic expression of ZNF207-
HER2 and MDK-HER2 in the NIH/3T3 cells led to a con-
stitutive activation of HER2 and downstream signaling, and
thus, cell transformation in vitro and tumorigenesis in vivo,
demonstrating the oncogenic driver of the fusions. Further-
more, the xenografts ectopically expressing MDK-HER2
but not ZNF207-HER2 were sensitive to trastuzumab.
Interestingly, the HER2 fusions were found to be mutually
exclusive with mutations of PI3KCA, BRAF, KRAS, and
HER3 and amplifications of FGFR2 and c-MET. Collect-
ively, our data confirmed for the first time the presence of
oncogenic HER2 arrangements in patients with GC. The
ZNF207-HER2 fusion represents a novel intrinsic resist-
ance mechanism to trastuzumab-based anti-HER2 therapy,
due to the loss of binding ability to trastuzumab.
Despite the overall survival benefit achieved with tras-
tuzumab in GC patients carrying HER2 amplification, a
significant portion of the patients do not respond clinic-
ally to the treatment, and there is little understanding of
the molecular mechanism underlying this intrinsic re-
sistance. In contrast, the understanding of the mecha-
nisms of both intrinsic and acquired resistance to HER2
inhibitors in HER2-positive BC is far more advanced[15,23]. For example, some intrinsic resistance mecha-
nisms affect the ability of HER2 inhibitors to directly en-
gage HER2 in BC; a truncated form of HER2, p95,
lacking the trastuzumab binding region [24,25]; a splice
variant that eliminates exon 16 (HER2-Δ16) in the extra-
cellular domain of the HER2 receptor, preventing disrup-
tion of HER2 homodimers upon binding by trastuzumab
[26]; In our study, we did not assess p95, but we did
find HER2-Δ16 in a GC tumor sample, which naturally
harbored HER2-Δ16. Surprisingly, its corresponding
patient-derived gastric cancer xenograft (PDGCX), which
retains HER2-Δ16 (data not shown), responded well to
trastuzumab treatment, with a significant tumor regression
being observed (data not shown). Given the lack of clinical
evidence of association between HER2-Δ16 and resistance
to trastuzumab in BC, as well as the lack of preclinical data
on the anti-tumor efficacy of trastuzumab in xenografts
carrying HER2-Δ16 [26], our data suggest that HER2-Δ16
was not a resistance mechanism to trastuzumab in GC
when tested in the PDGCX model. Additional HER2-Δ16
positive PDGCX models are warranted to confirm this ob-
servation further.
Surprisingly, in addition to the HER2 fusions, we also
found two recurrent in-frame BRAF fusion transcripts,
BAIAP2L1-BRAF (data not shown), in another cohort of
HER2-amplified GC patients. Although further work is
needed to demonstrate its oncogenic activity and sensitivity
to trastuzumab or BRAF inhibitor, the findings suggest that
BAIAP2L1-BRAF could be a potential resistance mechan-
ism to trastuzumab, as it maintains an intact BRAF kinase
domain [27].
The current clinical protocol for selecting HER2-
positive patients is based on FISH positivity or an IHC
(HercepTest™) score of 3+ (HercepTest™ score of 2+
needs further FISH confirmation). HER2 gene amplifica-
tion is determined by the ratio between the numbers of sig-
nals from the hybridization of the HER2 gene probe (covers
the whole HER2 gene) and the number of signals from the
hybridization of the reference chromosome 17 centromere
probe [28]. The antibody used in the HercepTest™ recog-
nizes the HER2 epitope located at the HER2 intracellular
site, which is also covered by all three HER2 fusions
(Figure 1A). Therefore, the current HER2 tests cannot
distinguish between the amplifications of the HER2 fu-
sions and that of the wild-type. The use of multicolor
FISH and RT-PCR assays to detect the HER2 fusions
developed in this study demonstrated the feasibility of
detecting HER2 fusions as clinical biomarkers in either
FFPE or frozen surgical GC specimens. This finding
warrants further clinical validation of the novel resistant
mechanism of the ZNF207-HER2 fusion to trastuzumab-
based therapy.
In addition to the antibody, a number of small-
molecule HER2 kinase inhibitors are available: lapatinib,
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tinib and neratinib, two irreversible kinase inhibitors, cur-
rently in phase III clinical trials for HER2-positive BC.
The modulation of AKT signaling by lapatinib in the cells
expressing the HER2 fusions (Figure 5A) suggests that the
small-molecule inhibitor against HER2 kinase is a poten-
tial option for cancer patients with the HER2 fusions. This
notion is further supported by our observations that NIH/
3T3 cells expressing either ZNF207-HER2 or MDK-HER2
showed to be sensitivity to lapatinib, afatinib, and nerati-
nib in vitro (data not shown).
Besides the functional and phonotypical heterogeneity,
emerging evidences indicate that genetic heterogeneity
among tumor cells contributes to the advantages for sur-
vival, proliferation, metastasis and resistance to anti-cancer
therapies. Recently, Tajiri et al. examined 475 GC samples
using multiple ligation-dependent probe amplification
(MLPA) and FISH analysis and revealed intratumoral het-
erogeneity of HER2 amplification in 41% (21/51) of HER2-
amplified tumors. The mutually exclusive co-amplification
of HER2 with EGFR, FGFR2, FGFR2 andMET was also ob-
served respectively in some of the tumors, suggesting the
potential challenges for design of targeted-therapy ap-
proaches [29]. The homogenous expression of ZNF270-
HER2 supports the driver role of this fusion gene, which
is consistent with our experimental results. However, the
advantage of co-amplification of MDK-HER2 and NOS2-
HER2 with wild HER2 (intra-tumor heterogeneity) is yet
to be uncovered. Further studies to explore the respon-
siveness of the HER2 fusions to combination of trastuzu-
mab with pertuzumab or chemotherapies may lead to
additional insights into the impact of the HER2 fusions to
anti-HER2 therapies.
It is noteworthy that the HER2 positive GC samples
used for this study were collected prior the introduction
of trastuzumab to China, thus we lack evidence for clin-
ical response of the tumors harboring HER2 fusions to
trastuzuamb. Further studies on GC samples from pa-
tients treated with trastuzumab at different stages will
help to confirm the effect of the HER2 fusions to tras-
tuzmab therapy and their oncogenic property.
Although further large-scale clinical investigations are
needed to understand the clinical prevalence in GC pa-
tients, our data on ZNF207-HER2, along with the discov-
ery of two recurrent BAIAP2L1-BRAF, strongly indicate a
large degree of molecular heterogeneity, even in the well-
defined HER2-positive segment, representing potential
de novo resistance to trastuzumab-based GC therapies.
In addition, whether a similar mechanism would exist
in BC also needs to be exploited.
Conclusions
In summary, we uncovered three previously unidentified
HER2 fusion genes in GC patients whose tumors wereclinically classified as HER2-positive. Our results suggest
that these HER2 fusions are genetically amplified driver on-
cogenes that respond differently to the HER2-neutralizing
antibody trastuzumab. The resistance of ZNF207-HER2 to
trastuzumab and the existence of the recurrent BRAF
fusion variants warrant molecular subtype diagnoses of
HER2-positive GC patients for more effective person-
alized trastuzumab therapies and for future treatment
options.
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